http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S61109736-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_791a12238f4b0a48e55a67dca4ee4923 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
| filingDate | 1984-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00a2535d747257a551c40a44e3d582bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c32bf1255925e6f6512e48da7ca5f4c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59b5fe31c3d8eae214fef16ca2653e40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47d20d6438e5ca72718254c6d5d5bdca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b6ce9e3f228f736229c1a66a4a0e32f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3fd2b328de691baa4832b48251226a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85dcb6322f00b6467c532529d086cb76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af7407933b6b77b23be7c3bb54f42c9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b1b2d8776e9d97008c4702e9f37360 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a98313995bd0cd2c4ced02431f50280a |
| publicationDate | 1986-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S61109736-A |
| titleOfInvention | Drug for external use |
| abstract | PURPOSE: To provide a drug for external use, having improved releasability of the principal drug without causing the decomposition of the drug, and useful for the surgical treatment and prevention of various infectious diseases, by adding negamycin or its salt as an active component to a gelatinous base, and adding cyclodextrin to the mixture. n CONSTITUTION: Negamycin (abbreviated as NGM) or its salt and cyclodextrin are added to a gelatinous base. NGM is effective for the remedy of various infectious diseases (e.g. impetigo, folliculitis, sycosis vulgaris, superficial pyoderma, etc.) caused by Gram-positive bacteria and Gram-negative bacteria represented by Pseudomonas aeruginosa, and its resistant strain, however, it has the problems of stability in the base and the releasability from the base when used as an external drug. It has been found that the concentration of NGM can be increased rapidly to the bactericidal level and the decomposition of the principal drug can be prevented by using the agent in combination with cyclodextrin and a gelatinous base (e.g. carboxyvinyl polymer). Since a gelatinous base is used in the present drug, it is free from fat and oil, suitable even to seborrheic diseases, and fixed firmly to the mucosa and damaged moist part. n COPYRIGHT: (C)1986,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S62292719-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0466452-B2 |
| priorityDate | 1984-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.